Case of Aicardi-Goutières syndrome diagnosed in adulthood on whole-genome sequencing.

IF 2.6 Q3 CLINICAL NEUROLOGY
BMJ Neurology Open Pub Date : 2026-07-20 eCollection Date: 2026-01-01 DOI:10.1136/bmjno-2025-001407
Lewis Cobb, Jayant Kumar, Amit Roy, Sarah Walsh, Una-Marie Sheerin
{"title":"Case of Aicardi-Goutières syndrome diagnosed in adulthood on whole-genome sequencing.","authors":"Lewis Cobb, Jayant Kumar, Amit Roy, Sarah Walsh, Una-Marie Sheerin","doi":"10.1136/bmjno-2025-001407","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background</b>: Aicardi-Goutières syndrome (AGS) is a neurogenetic leukoencephalopathy that typically manifests within the first 6 months of life. Classically, AGS presents with an early encephalopathic episode characterised by feeding difficulties, irritability and psychomotor regression or delay. Cutaneous lesions affecting the extremities and epilepsy are common, with symptoms usually evolving over weeks to months before stabilising. Milder phenotypes have been described, often demonstrating relative preservation of language and cognitive function. <b>Case presentation</b>: Here, we report a case of a 31-year-old woman with compound heterozygous variants in the <i>ADAR</i> gene: (GRCh38) NM_001111.4:c.577C>G p.(Pro193Ala) and (GRCh38) NM_001111.4:c.1111_1112del p.(Ser371Cysfs*3), consistent with AGS. The developmental history revealed normal early motor milestones. At age 3, she developed progressive ataxia and hypotonia. Over time, she exhibited spasticity, dystonia and learning difficulties, along with significant cardiac valvular calcification. <b>Conclusions</b>: The patient was recently referred for consideration of treatment with baricitinib, a selective JAK1/JAK2 inhibitor. This case underscores the importance of considering AGS in individuals with non-classical presentations, particularly when extracerebral calcification is a notable feature.</p>","PeriodicalId":52754,"journal":{"name":"BMJ Neurology Open","volume":"8 2","pages":"e001407"},"PeriodicalIF":2.6000,"publicationDate":"2026-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13386073/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMJ Neurology Open","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/bmjno-2025-001407","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Aicardi-Goutières syndrome (AGS) is a neurogenetic leukoencephalopathy that typically manifests within the first 6 months of life. Classically, AGS presents with an early encephalopathic episode characterised by feeding difficulties, irritability and psychomotor regression or delay. Cutaneous lesions affecting the extremities and epilepsy are common, with symptoms usually evolving over weeks to months before stabilising. Milder phenotypes have been described, often demonstrating relative preservation of language and cognitive function. Case presentation: Here, we report a case of a 31-year-old woman with compound heterozygous variants in the ADAR gene: (GRCh38) NM_001111.4:c.577C>G p.(Pro193Ala) and (GRCh38) NM_001111.4:c.1111_1112del p.(Ser371Cysfs*3), consistent with AGS. The developmental history revealed normal early motor milestones. At age 3, she developed progressive ataxia and hypotonia. Over time, she exhibited spasticity, dystonia and learning difficulties, along with significant cardiac valvular calcification. Conclusions: The patient was recently referred for consideration of treatment with baricitinib, a selective JAK1/JAK2 inhibitor. This case underscores the importance of considering AGS in individuals with non-classical presentations, particularly when extracerebral calcification is a notable feature.

全基因组测序诊断成人aicardii - gouti综合征1例。
背景:aicardii - gouti综合征(AGS)是一种神经遗传性白质脑病,通常在出生后6个月内出现。典型地,AGS表现为早期脑病发作,其特征是进食困难、易怒和精神运动倒退或延迟。影响四肢和癫痫的皮肤病变是常见的,症状通常在几周到几个月后才稳定下来。温和的表型已被描述,通常显示相对保存的语言和认知功能。病例介绍:在这里,我们报告了一例31岁女性ADAR基因复合杂合变异体:(GRCh38) NM_001111.4:c.577C> gp。(Pro193Ala)和(GRCh38) NM_001111.4:c。1111_1112del p.(Ser371Cysfs*3),与AGS一致。发育历史显示正常的早期运动里程碑。3岁时,她出现进行性共济失调和张力减退。随着时间的推移,她表现出痉挛、肌张力障碍和学习困难,并伴有明显的心脏瓣膜钙化。结论:该患者最近考虑使用baricitinib治疗,baricitinib是一种选择性JAK1/JAK2抑制剂。该病例强调了在非经典表现的个体中考虑AGS的重要性,特别是当脑外钙化是一个显著特征时。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
BMJ Neurology Open
BMJ Neurology Open Medicine-Neurology (clinical)
CiteScore
3.20
自引率
3.70%
发文量
46
审稿时长
13 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书